Sandbox Reserved 383: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 30: | Line 30: | ||
Proc. Natl. Acad. Sci. U.S.A. 103:10753-10758(2006) [PubMed: 16809426] [Abstract]</ref> Disorders that are linked to variations in the DRD3 gene include social phobia<ref>Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M (2000). "Low dopamine D(2) receptor binding potential in social phobia". Am J Psychiatry 157 (3): 457–459. doi:10.1176/appi.ajp.157.3.457. PMID 10698826.</ref>, Tourette’s syndrome<ref>11Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557.</ref>, Parkinson’s disease<ref>Fuxe K, Manger P, Genedani S, Agnati L (2006). The nigrostriatal DA pathway and Parkinson’s disease. "The nigrostriatal DA pathway and Parkinson's disease". J Neural Transm Suppl. Journal of Neural Transmission. Supplementa 70 (70): 71–83. doi:10.1007/978-3-211-45295-0_13. ISBN 978-3-211-28927-3. PMID 17017512.</ref>, schizophrenia<ref11Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557./>, neuroleptic malignant syndrome<ref>13Mihara K, Kondo T, Suzuki A, et al. (2003). "Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome". Am. J. Med. Genet. B Neuropsychiatr. Genet. 117 (1): 57–60. doi:10.1002/ajmg.b.10025. PMID 12555236.</ref>, attention-deficit hyperactivinty disorder (ADHD)<ref>Faraone S, Khan S (2006). "Candidate gene studies of attention-deficit/hyperactivity disorder". J Clin Psychiatry 67 Suppl 8: 13–20. PMID 16961425.</ref>, and drug and alcohol dependence<ref11Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557./><ref>Hummel M, Unterwald E (2002). "D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action". J Cell Physiol 191 (1): 17–27. doi:10.1002/jcp.10078. PMID 11920678</ref>. | Proc. Natl. Acad. Sci. U.S.A. 103:10753-10758(2006) [PubMed: 16809426] [Abstract]</ref> Disorders that are linked to variations in the DRD3 gene include social phobia<ref>Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M (2000). "Low dopamine D(2) receptor binding potential in social phobia". Am J Psychiatry 157 (3): 457–459. doi:10.1176/appi.ajp.157.3.457. PMID 10698826.</ref>, Tourette’s syndrome<ref>11Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557.</ref>, Parkinson’s disease<ref>Fuxe K, Manger P, Genedani S, Agnati L (2006). The nigrostriatal DA pathway and Parkinson’s disease. "The nigrostriatal DA pathway and Parkinson's disease". J Neural Transm Suppl. Journal of Neural Transmission. Supplementa 70 (70): 71–83. doi:10.1007/978-3-211-45295-0_13. ISBN 978-3-211-28927-3. PMID 17017512.</ref>, schizophrenia<ref11Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557./>, neuroleptic malignant syndrome<ref>13Mihara K, Kondo T, Suzuki A, et al. (2003). "Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome". Am. J. Med. Genet. B Neuropsychiatr. Genet. 117 (1): 57–60. doi:10.1002/ajmg.b.10025. PMID 12555236.</ref>, attention-deficit hyperactivinty disorder (ADHD)<ref>Faraone S, Khan S (2006). "Candidate gene studies of attention-deficit/hyperactivity disorder". J Clin Psychiatry 67 Suppl 8: 13–20. PMID 16961425.</ref>, and drug and alcohol dependence<ref11Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557./><ref>Hummel M, Unterwald E (2002). "D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action". J Cell Physiol 191 (1): 17–27. doi:10.1002/jcp.10078. PMID 11920678</ref>. | ||
==References== | ==References== | ||
<Girault J, Greengard P (2004). "The neurobiology of dopamine signaling". Arch Neurol 61 (5): 641–4. doi:10.1001/archneur.61.5.641. PMID 15148138./> | |||
<Le Coniat M, Sokoloff P, Hillion J, Martres MP, Giros B, Pilon C, Schwartz JC, Berger R (Oct 1991). "Chromosomal localization of the human D3 dopamine receptor gene". Hum Genet 87 (5): 618–20./> | |||
<National Center for Biotechnology Information, U.S. National Library of Medicine. DRD3 dopamine receptor D3 [Homo sapiens]. 19 November 2011./> | |||
<"G protein-coupled receptor kinase 4 (GRK4) regulates the phosphorylation and function of the dopamine D3 receptor." | |||
Villar V.A.M., Jones J.E., Armando I., Palmes-Saloma C., Yu P., Pascua A.M., Keever L., Arnaldo F.B., Wang Z., Luo Y., Felder R.A., Jose P.A. | Villar V.A.M., Jones J.E., Armando I., Palmes-Saloma C., Yu P., Pascua A.M., Keever L., Arnaldo F.B., Wang Z., Luo Y., Felder R.A., Jose P.A. | ||
J. Biol. Chem. 284:21425-21434(2009) [PubMed: 19520868] [Abstract]/> | J. Biol. Chem. 284:21425-21434(2009) [PubMed: 19520868] [Abstract]/> | ||
<http://www.pdb.org/pdb/explore.do?structureId=3PBL/> | |||
<http://en.wikipedia.org/wiki/Category:Dopamine_agonists/> | |||
<http://en.wikipedia.org/wiki/Category:Dopamine_antagonists/> | |||
<"Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families." | |||
Lucotte G., Lagarde J.-P., Funalot B., Sokoloff P. | Lucotte G., Lagarde J.-P., Funalot B., Sokoloff P. | ||
Clin. Genet. 69:437-440(2006) [PubMed: 16650084] [Abstract]/> | Clin. Genet. 69:437-440(2006) [PubMed: 16650084] [Abstract]/> | ||
<"A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor." | |||
Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.-P., Lucotte G., Sokoloff P. | Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.-P., Lucotte G., Sokoloff P. | ||
Proc. Natl. Acad. Sci. U.S.A. 103:10753-10758(2006) [PubMed: 16809426] [Abstract]/> | Proc. Natl. Acad. Sci. U.S.A. 103:10753-10758(2006) [PubMed: 16809426] [Abstract]/> | ||
<Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M (2000). "Low dopamine D(2) receptor binding potential in social phobia". Am J Psychiatry 157 (3): 457–459. doi:10.1176/appi.ajp.157.3.457. PMID 10698826./> | |||
<Kienast T, Heinz A (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets 5 (1): 109–31. doi:10.2174/187152706784111560. PMID 16613557./> | |||
<Fuxe K, Manger P, Genedani S, Agnati L (2006). The nigrostriatal DA pathway and Parkinson’s disease. "The nigrostriatal DA pathway and Parkinson's disease". J Neural Transm Suppl. Journal of Neural Transmission. Supplementa 70 (70): 71–83. doi:10.1007/978-3-211-45295-0_13. ISBN 978-3-211-28927-3. PMID 17017512./> | |||
<Mihara K, Kondo T, Suzuki A, et al. (2003). "Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome". Am. J. Med. Genet. B Neuropsychiatr. Genet. 117 (1): 57–60. doi:10.1002/ajmg.b.10025. PMID 12555236./> | |||
Faraone S, Khan S (2006). "Candidate gene studies of attention-deficit/hyperactivity disorder". J Clin Psychiatry 67 Suppl 8: 13–20. PMID 16961425./> | |||
Hummel M, Unterwald E (2002). "D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action". J Cell Physiol 191 (1): 17–27. doi:10.1002/jcp.10078. PMID 11920678/> | |||
